Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
Inventors
Wang, Jing • Patterson, Troy David • TIAN, ZE
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The invention provides a method of treating cancer in a subject in need thereof, comprising administering to the subject: (a) a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or an acyl group; and (b) a PD-1 signaling inhibitor; wherein the compound of Formula I or pharmaceutically acceptable salt thereof and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The invention further provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, a PD-1 signaling inhibitor and a pharmaceutically acceptable carrier or excipient.
Core Innovation
The invention is directed to a method of treating colon carcinoma in a subject in need thereof by administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a PD-1 signaling inhibitor. The compound and the PD-1 signaling inhibitor are administered in amounts which in combination are therapeutically effective. The disclosure frames the approach as cancer treatment using a PI3K/HDAC-targeting compound of Formula I, including a zinc-binding moiety, as a combination partner with PD-1 pathway blockade.
The compound of Formula I is described with substituent options such that R can be hydrogen or acyl, and with preferred A groups including methoxy-pyridyl and methoxy-pyrimidyl patterns. Compound 1 is identified as a lead example with PI3K and HDAC inhibitory activity, antiproliferative effects, and tumor-related pharmacodynamic activity in xenograft models. The combination with PD-1 signaling inhibitors is presented as enabling preventing or treating cancer, with possible synergy and combined therapeutic intent.
The disclosure also describes pharmaceutical composition formulations associated with the compounds, including salts such as methanesulfonate, sodium, potassium, and choline, and references synthesis scaffolding for example compounds. The combination approach is described in terms of co- or sequential administration at a general level, and it is supported by references to tumor model observations and an Ames test safety/genotoxicity profile. The overall core innovation is the therapeutic combination of a Formula I PI3K/HDAC-targeting compound with a PD-1 signaling inhibitor for colon carcinoma treatment in a therapeutically effective combined amount.
Claims Coverage
The independent claim covers a therapeutically effective combination for colon carcinoma comprising one compound of Formula I, or a pharmaceutically acceptable salt, and one PD-1 signaling inhibitor. Dependent claims refine the PD-1 axis target, identify specific inhibitor agents, optionally require administration together in one composition, and narrow to monoclonal antibody embodiments including pembrolizumab.
Therapeutically effective combination for colon carcinoma
A method of treating colon carcinoma in a subject in need thereof by administering a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a PD-1 signaling inhibitor in amounts which in combination are therapeutically effective.
PD-1 pathway ligand/receptor targeting
The PD-1 signaling inhibitor inhibits one or more of PD-1, PD-L1, and PD-L2.
Selected PD-1 signaling inhibitor agents
The PD-1 signaling inhibitor is selected from pembrolizumab, nivolumab, atelolizumab, avelumab, durvalumab, or pidilizumab.
Co-administration in a single composition
The compound of Formula I, or a pharmaceutically acceptable salt, and the PD-1 signaling inhibitor are administered together in one composition.
Monoclonal antibody PD-1 signaling inhibitor class
The PD-1 signaling inhibitor is selected from an anti-PD-1, anti-PD-L1, or anti-PD-L2 monoclonal antibody.
Pembrolizumab as an anti-PD-1 monoclonal antibody
The anti-PD-1 monoclonal antibody is pembrolizumab.
Across the independent claim and its refinements, the core claim coverage is directed to colon carcinoma treatment using a Formula I compound, or pharmaceutically acceptable salt, combined with a PD-1 signaling inhibitor in therapeutically effective combined amounts, with further limitations specifying PD-1, PD-L1, or PD-L2 targeting, named inhibitor agents, administration together in one composition, and anti-PD-1, anti-PD-L1, or anti-PD-L2 monoclonal antibodies including pembrolizumab.
Stated Advantages
Therapeutically effective prevention or treatment of cancer, including colon carcinoma, using the combination of a Formula I compound with a PD-1 signaling inhibitor.
Referenced favorable safety/genotoxicity profile based on an Ames test.
Documented Applications
Treating colon carcinoma in a subject in need thereof by administering a compound of Formula I, or pharmaceutically acceptable salt, together with a PD-1 signaling inhibitor in therapeutically effective combined amounts.
Interested in licensing this patent?